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Abstract
Introduction: This study investigated whether the calcineurin inhibitor, tacrolimus, suppresses receptor activator of
NF-B ligand (RANKL) expression in fibroblast-like synoviocytes (FLS) through regulation of IL-6/Janus activated
kinase (JAK2)/signal transducer and activator of transcription-3 (STAT3) and suppressor of cytokine signaling
(SOCS3) signaling.
Methods: The expression of RANKL, JAK2, STAT3, and SOCS3 proteins was assessed by western blot analysis, real-
time PCR and ELISA in IL-6 combined with soluble IL-6 receptor (sIL-6R)-stimulated rheumatoid arthritis (RA)-FLS with
or without tacrolimus treatment. The effects of tacrolimus on synovial inflammation and bone erosion were assessed
using mice with arthritis induced by K/BxN serum. Immunofluorescent staining was performed to identify the effect
of tacrolimus on RANKL and SOCS3. The tartrate-resistant acid phosphatase staining assay was performed to assess
the effect of tacrolimus on osteoclast differentiation.
Results: We found that RANKL expression in RA FLS is regulated by the IL-6/sIL-6R/JAK2/STAT3/SOCS3 pathway.
Inhibitory effects of tacrolimus on RANKL expression in a serum-induced arthritis mice model were identified.
Tacrolimus inhibits RANKL expression in IL-6/sIL-6R-stimulated FLS by suppressing STAT3. Among negative
regulators of the JAK/STAT pathway, such as CIS1, SOCS1, and SOCS3, only SOCS3 is significantly induced by
tacrolimus. As compared to dexamethasone and methotrexate, tacrolimus more potently suppresses RANKL
expression in FLS. By up-regulating SOCS3, tacrolimus down-regulates activation of the JAK-STAT pathway by IL-6/
sIL-6R trans-signaling, thus decreasing RANKL expression in FLS.
Conclusions: These data suggest that tacrolimus might affect the RANKL expression in IL-6 stimulated FLS through
STAT3 suppression, together with up-regulation of SOCS3.
Introduction
Receptor activator of NF-B ligand (RANKL) is a trans-
membrane protein of the TNF superfamily, which is an
important molecule in bone metabolism [1]. RANKL,
together with macrophage colony-stimulating factor
(M-CSF), is an essential molecule in osteoclast formation
through its role in the differentiation of osteoclast pre-
cursor cells into multinuclear osteoclast-like cells with
bone resorbing activity. RANKL produced by infiltrating
active T cells and macrophages was highly detectable in
the synovial tissues of subjects with active rheumatoid
arthritis (RA) [2,3]. Fibroblast-like synoviocytes (FLS),
which are stimulated by IL-6, TNF-a and IL-17, are crucial
cells that produce RANKL in the inflammatory joints of
patients with RA [3-5]. These findings suggest that
RANKL has an important role in bone resorption and loss,
with FLS acting as a major producer of RANKL in RA.
The IL-6 and IL-6R complex leads to homodimerization
of the cell surface molecule, gp130, which subsequently
transduces a signal that activates intracytoplasmic Janus
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activated kinase (JAK) tyrosine kinase. JAK tyrosine kinase
preferentially induces tyrosine phosphorylation of signal
transducer and activator of transcription 3 (STAT3) [6].
In addition to roles of STAT3 in cell survival, growth, and
differentiation [7], STAT3 is closely related to osteoclasto-
genesis [8]. RANKL, induced by the IL-6/sIL-6R complex,
requires activation of STAT3 [8,9]. Although the roles of
suppressor of cytokine signaling/cytokine-inducible SH2
(SOCS/CIS) have been retained, both SOCS1 and SOCS3
negatively regulate JAK tyrosine kinase as feedback inhi-
bitors [6]. Shouda et al. demonstrated that inflammatory
changes in joints and bone erosion were significantly sup-
pressed in a collagen-induced arthritis animal model trea-
ted with SOCS-3 [10]. Therefore, regulation of STAT3
and SOCS3 in the FLS of patients with RA through the
IL-6/gp130/STAT3 signaling pathway might be a potent
therapeutic strategy in the treatment of RA.
Tacrolimus (FK506) is a macrolide immunosuppressant
that primarily interferes with T cell activation and proli-
feration through inhibition of calcineurin, a calcium-
dependent phosphatase that activates the nuclear factor
of activated T cells (NFAT) transcription factor [11]. In
addition to the anti-arthritic effects of tacrolimus through
regulation of inflammatory cytokine production in RA
[12,13], there is some evidence that tacrolimus may have
a role in the regulation of bone metabolism. Tacrolimus
prevents differentiation of these cells into mature osteo-
clasts through the calcineurin-NFAT pathway [14,15].
Tacrolimus was shown to have a protective effect on
bone resorption in rats [16].
The blockade of RANKL expression in FLSmay be impor-
tant in the regulation of osteoclast differentiation for bone
erosion in RA, because FLS is a potent source of RANKL
production in patients with RA. In the current study, we
investigated the potential roles of a calcineurin inhibitor,
tacrolimus, in the regulation of RANKL expression through
the IL-6-induced JAK-STAT signaling pathway in RA FLS.
Methods
Cell culture
Synoviocytes were isolated from the synovial tissues of
four patients with RA (three women and one man) dur-
ing total knee replacement surgery. Patients with RA met
the American College of Rheumatology 1987 revised
classification criteria for RA diagnosis [17]. Synovial
tissues were harvested and incubated with collagenase
type I (1 mg/ml) and hyaluronidase type I (2 mg/ml) for
2 hours at 37°C. After removing the large tissue, floating
cells and synovial fibroblasts were isolated from adherent
cells. Synovial fibroblasts were maintained in (D)MEM
(Gibco, BRL, Grand Island, NY, USA) supplemented with
10% fetal bovine serum (Hyclone, Logan, UT, USA),
100 U/ml penicillin, and 100 μg/ml streptomycin. Subcul-
tures were performed when cells reached 80% to 90%
confluence. For the experiments, cells from passages three
to eight were used. The protocol of this study was
approved by the Institutional Review Board/Ethics Com-
mittee at the Catholic University of Daegu. Informed
consent was obtained from the patients at the time of
study enrollment.
Viability assay
Cell viability was measured by the 3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetra zolium bromide (MTT) assay
(Sigma, St. Louis, MO, USA). Cells (2 × 104 cells/ml)
were seeded in 96-well plates and incubated for 24 hours.
Media were removed and cells were treated with different
doses of drugs and incubated for 24 hours. An MTT
(0.5 mg/ml) solution of 50 µl was added to each well.
After incubation at 37°C for 4 hours, the MTT solution
was removed and 100 µl of dimethyl sulfoxide (DMSO)
was added. Cells were incubated at room temperature for
an additional 10 minutes after which absorbance was
measured at 540 nm with a plate reader (BMG Lab Tech-
nologies, Offenburg, Germany).
Preparation of arthritis models and treatment
C57BL/6 mice (SLC Inc., Shizuoka, Japan) weighing 20
to 25 g at the beginning of the experiment were allo-
cated to each study group, such as control mice (n = 6),
mice treated with tacrolimus (n = 6), and mice not treated
with tacrolimus (n = 6). K/BxN serum was provided by SI
Lee (Gyeongsang National University School of Medicine,
Jinju, Gyeongnam, Republic of Korea). We also appreciate
the great contribution to this experiment of KRN TCR
transgenic mice provided by D. Mathis and C. Benoist
(Harvard Medical School, Boston, MA, USA) for the
preparation of the K/BxN serum-induced arthritis. All
experimental animals used in this study were maintained
under the protocol approved by the Institutional Animal
Care and Use Committee of the Gyeongsang National
University (GLA-101116-M0112). Tacrolimus (1 mg/kg)
was intraperitoneally injected into the mice four times a
week. In the control group, normal saline was injected at
the same frequency. C57BL/6 mice treated with/without
tacrolimus subsequently received intraperitoneal injections
of 150 μl of K/BxN serum. Following treatment, the mice
were monitored daily for signs of arthritis. Ankle thickness
was evaluated with a steel vernier caliper.
Histopathological scoring was performed on the knee
joints of mice in each experimental group as previously
described [18]. Six H & E-stained sections per each
experimental animal were scored by two independent
observers (K-Y Park and S-K Kim) at both low and high
power fields. Scores ranged from 0 (normal) to a maxi-
mum of 5 (severe infiltration of inflammatory cells for
inflammation, full thickness defect in the cortical bone,
and marked trabecular bone loss for bone erosion).
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Quantitative real time-polymerase chain reaction (RT-PCR)
Cells were plated at a density of 2 × 106 cells per 100 mm
on culture dishes and pretreated with 100 ng/ml IL-6/
sIL-6R for 24 hours at 37°C. Various concentrations of
tacrolimus (10, 100 and 1,000 nM) were then added to
the culture for 24 hours at 37°C. Total RNA was
extracted from the cells and the wrists sampled from
sacrificed experimental mice using Trizol reagent (Gibco
BRL, Grand Island, NY, USA). RNA was reverse tran-
scribed to complementary DNA using the Improm-II
Reverse Transcription System (Promega, Madison, WI,
USA). A total of 1 μg RNA was mixed with Oligo(dT)15
primer (0.5 μg/μL; Promega) and heated to 70°C for
5 minutes and 4°C for 5 minutes. Reverse transcription
was added to the 100U reaction buffer along with
0.5 mM deoxynucleoside triphosphate (dNTP), 4 mM
MgCl2, 1 mM DTT, 5U Improm II reverse transcriptase,
and 20 U recombinant ribonuclease inhibitor (RNasin).
Nuclease free water was added in a final volume of 20 µL,
and the reaction was annealed at 25°C for 5 minutes
followed by extension at 42°C for 1 hour.
RT-PCR was performed using the Mini Option TM
RT-PCR system (Bio-Rad, Hercules, CA, USA) with the
DyNAmo SYBR Green qPCR kit (FINNZYMES, Espoo,
Finland) according to the manufacturers’ instructions.
The reaction was performed in a total volume of 20 µL
containing 10 µL of master mix, 10 pmol/L of each
primer, 1 µL of cDNA, and 7 µL of distilled water. The
following PCR protocols were used: 95°C for 3 minutes;
40 cycles (15 seconds, 95°C/1 minute, 60°C); and 72°C/
45 seconds; and 60°C to 95°C per cycle for melting
curve analysis.
RANKL primer sequences were forward 5′-GCT TGA
AGC TCA GCC TTT TG-3′ and reverse 5′-CGA AAG
CAA ATG TTG GCA TA-3′. Osteoprotegerin (OPG)
primer sequences were forward 5′-GAA CCC CAG
AGC GAA ATA CA-3′ and reverse 5′-TAT TCG CCA
ACT GAG CA-3′. The b-actin primer sequences were
forward 5′-CTG GAA CGG TGA AGG TGA CA-3′
and reverse 5′-AAG GGA CTT CCT GTA ACA CA-3′.
Primers were synthesized by Bionics (Seoul, Korea).
Data were analyzed with the delta delta Ct method.
Western blot analyses
Cells were treated with 0, 30, 50, and 100 ng/ml IL-6/
sIL-6R for 30 minutes. For another experiment, cells
were treated with 100 ng/ml IL-6/sIL-6R for 30 minutes
before the addition of one of two different concentra-
tions of tacrolimus (0.5 or 1 µM). After incubation
for 24 hours, cell (4 × 106) pellets were lysed in a lysis
buffer composed of 1 M Tris-HCl pH 8.0, 5 M NaCl,
10% Nonidet P40, and one tablet of protease inhibitor
cocktail (Roche, Indianapolis, IN, USA). Cells were then
incubated on ice for 10 minutes and centrifuged at
12,000 rpm for 10 minutes at 4°C. The pellet was dis-
carded and the total protein concentration in the super-
natant was determined using the Bio-Rad protein assay
kit (Bio-Rad, Hercules, CA, USA). Proteins (30 to 60 μg)
were separated by 10% SDS-PAGE gel electrophoresis,
transferred to nitrocellulose membranes (Bio-Rad), and
probed with appropriate antibodies. Antibodies to
p-STAT3 (Y705), STAT3, and RANKL were obtained
from Santa Cruz Biotechnology (Santa Cruz, CA, USA).
Antibodies to p-JAK2 (Tyr1007/1008), JAK2, nuclear
factor-B (NF-B), p-NF-B, and NFAT were obtained
from Cell Signaling Technology (Beverly, MA, USA).
Antibodies to OPG and SOCS3 were purchased from
Abcam (Cambridge, UK). Primary antibodies were incu-
bated overnight at 4°C and horseradish peroxidase-
conjugated secondary antibodies were incubated for
1 hour at room temperature. Proteins were detected
with the SuperSignal® West Pico chemiluminescent kit
(Thermo Scientific, Rockford, IL, USA). Densitometry
values were analyzed and quantified with Quantity One
software (Bio-Rad).
Transfection of siRNA
Cells were plated at approximately 80% confluence and
transfected with siRNA via the lipofectamine® RNAi-
MAX reagent (Invitrogen, Carlsbad, CA, USA). The
siRNA for human SOCS3 and the Stealth™RNAi nega-
tive control were purchased from Invitrogen. SiRNA (50
nM) and lipofectamine® RNAiMAX reagent in Opti-
MEM (Invitrogen) were mixed and incubated at room
temperature for 20 minutes. The mixtures were then
added to each dish containing cells and incubated at
37°C for 72 hours. The transfected cells were treated
with IL-6/sIL-6R at 100 ng/ml for 30 minutes.
Enzyme-linked immunosorbent assay (ELISA)
A total of 2 × 104 cells were plated in 96-well culture
plates. Cells were stimulated by IL-6/sIL-6R at 100 ng/
ml for 24 hours followed by treatment with tacrolimus
(0.01, 0.1 and 1 µM), methotrexate (MTX) (1 µg), and
dexamethasone (1µg) for 24 hours at 37°C. RANKL and
OPG were measured using ELISA Kits (Uscn Life
Science Inc., Wuhan, China for RANKL and R&D Sys-
tems, Minneapolis, MN, USA for OPG) according to the
manufacturers’ instructions. ELISA plates with 96 wells
(Nunc, Rochester, NY, USA) were coated with 2 µg/ml
mouse monoclonal antihuman OPG and incubated over-
night at room temperature. After washing the plates,
recombinant human OPG standards and cell culture
supernatants were added. The detection antibody, bioti-
nylated polyclonal goat anti-human OPG at 200 ng/ml
and streptavidin-HRP conjugate were added. The plates
were washed again and hydrogen peroxide/tetramethyl-
benzidine substrate was added. The reaction was stopped
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and measured at 450 nm. Cell culture supernatants and
human RANKL standards were added to pre-coated
96-well ELISA plates for 2 hours at 37°C. Detection color
reagents A (H2O2) and B (TMB) were added for 1 hour,
washed, and then reacted with substrate solution for
20 minutes. Stop solution was added to stop the reaction
and absorbance was determined using a microplate
reader at 450 nm.
Immunofluorescence staining
Cells were seeded at a density of 5 × 104 cells on four-
well glass slides (Nunc). The cells were fixed with 3.7%
paraformaldehyde for 10 minutes at room temperature.
Afterwards, the slides were washed twice with PBS and
then blocked with 1% BSA in PBS for 30 minutes. Slides
were incubated with primary antibody diluted in PBS
for 1 hour. After washing with 0.1% Tween 20 in PBS,
the slides were incubated with donkey anti-goat IgG-
FITC or goat anti-rabbit IgG-FITC (Santa Cruz Biotech-
nology) for 40 minutes at room temperature in the dark.
Cover slips were mounted onto the slide and slides were
visualized by fluorescence microscopy (TE2000-U,
Nikon Instruments Inc., NY, USA).
Tartrate-resistant acid phosphatase (TRAP) staining
Peripheral blood mononuclear cells (PBMCs) were iso-
lated from human blood obtained from three female RA
patients by centrifugation using Histopaque®-1038
(Sigma-Aldrich, St. Louis, MO, USA) at 1800 rpm for
20 minutes at 4°C. Collected PBMCs (5 × 104 cells/well)
were incubated in 96 well plates containing 60 ng/ml of
RANKL and 50 ng/ml of M-CSF (Peprotech, East
Brunswick, NJ, USA) in the presence or absence of
tacrolimus. After 15 days, cells were fixed for 30 seconds
and stained with TRAP staining kit (Sigma-Aldrich).
Then, cells were incubated in a light protected incubator
for 1hour at 37°C. Counterstain to Gill’s hematoxylin
solution was used for 2 minutes. TRAP-positive multi-
nuclear cells were observed under a light microscope.
Statistical analysis
Data are expressed as the mean ± standard deviation of
three independent experiments. Statistical results were
analyzed using the Mann-Whitney test. Data were ana-
lyzed using SPSS version 13.0 for Windows (SPSS Inc.,
Chicago, IL, USA). P-values less than 0.05 were consid-
ered statistically significant.
Results
Expression of IL-6/sIL-6R-induced RANKL and OPG in RA
synoviocytes
RANKL and OPG are essential components in the regu-
lation of osteoclastogenesis. OPG is known to be a solu-
ble decoy receptor for RANKL, which functions to
inhibit RANKL-RANK interaction as well as osteoclast
maturation and activation. We found that IL-6/sIL-6R
increased RANKL expression in a dose-dependent man-
ner, whereas OPG expression after IL-6/sIL-6R treatment
was decreased compared to untreated cells (Figure 1A).
As illustrated in Figure 1B, treatment of each 100 ng
of IL-6/sIL-6R led to a prominent induction of p-JAK2
and p-STAT3. In addition, enhanced expression of
SOCS3 and RANKL might be induced by activation of
the JAK-STAT signaling pathway, which is stimulated
by IL-6/sIL-6R. Stronger expression of p-JAK2,
p-STAT3, and RANKL was detected in SOCS3 knock-
down FLS using SOCS3 siRNA following IL-6/sIL-6R
stimulation (Figure 1B).
Inhibitory effects of tacrolimus on RANKL expression in a
serum-induced arthritis model
Arthritis was successfully induced after injection of K/BxN
serum into C57B/L6 mice. Histological evaluations
demonstrated that joint destruction was significantly atte-
nuated in mice treated with tacrolimus compared to those
not treated, as evidenced by enhanced inflammatory cell
infiltration, cartilage abrasion, and bony erosion (Figure
2A). Compared to mice not treated with tacrolimus, mice
treated with tacrolimus had significantly thinner ankles, a
marker of joint inflammation, on day 8 and day 10 after
primary immunization (P <0.05 on day 8 and P <0.05 on
day 10) (Figure 2B). Semi-quantitative pathological analysis
was performed on knee joints and showed that synovial
inflammation and bony erosion were significantly reduced
in tacrolimus-treated arthritic mice compared to mice not
treated with tacrolimus (P <0.05 and P <0.05, respectively)
(Figure 2C).
RANKL gene expression in affected wrist joints is promi-
nently induced in serum-induced arthritis (Figure 2D).
However, tacrolimus was found to decrease RANKL expres-
sion in the arthritis model compared to mice not treated
with tacrolimus (P <0.05). In contrast, OPG gene expression
in arthritic mice was more induced in tacrolimus-treated
arthritis (P <0.05). These results indicate that tacrolimus
is involved in osteoclastogenesis in inflammatory arthritis.
In addition, tacrolimus significantly induced SOCS3
mRNA expression in affected joints of the arthritis model
compared to the non-treated arthritic animals (P <0.05).
Regulation of RANKL and OPG expression in the IL-6/sIL-
6R-stimulated FLS by tacrolimus
Tacrolimus markedly suppressed RANKL mRNA
expression in IL-6/sIL-6R-induced FLS (Figure 3A).
In contrast, OPG expression in IL-6/sIL-6R-induced FLS
was consistently increased at dosages of 100 and 1,000 nM
of tacrolimus (P <0.001 for both). Treatment with tacroli-
mus reduced RANKL production in the supernatants of
cells cultured under the same experimental conditions,
Choe et al. Arthritis Research & Therapy 2013, 15:R26
http://arthritis-research.com/content/15/1/R26
Page 4 of 12
whereas OPG concentrations were increased with tacroli-
mus treatment (Figure 3A).
Tacrolimus inhibited RANKL protein synthesis,
whereas it enhanced the expression of OPG protein
(Figure 3B). The presence of RANKL staining cells
among cultured FLS was minimal in the immunofluores-
cence assay (Figure 3C). Treatment with tacrolimus sig-
nificantly reduced the number of RANKL staining cells
compared to FLS stimulated with IL-6/sIL-6R alone.
In addition, we compared the efficacy of tacrolimus in
regulating RANKL and OPG expression to that of other
drugs including MTX and dexamethasone (Figure 3D).
All three experimental drugs showed inhibitory effects
on RANKL protein production (P <0.001 for tacrolimus,
P <0.05 for MTX, and P <0.05 for dexamethasone).
Regarding effects on OPG expression, tacrolimus and
MTX significantly enhanced OPG expression (P <0.001
for tacrolimus and P <0.01 for MTX), but dexametha-
sone did not (P >0.05).
The effects of tacrolimus on the JAK-STAT-SOCS3
signaling pathway
Phosphorylation of JAK2 and STAT3 in IL-6/sIL-6R-
stimulated FLS was significantly decreased by the addi-
tion of tacrolimus at doses of 0.5 and 1.0 µM (Figure 4A).
Co-stimulation with IL-6/sIL-6R consistently reduced
SOCS1, SOCS3 and CIS1 mRNA expression at the tran-
scriptional level; however, IL-6 mRNA expression was
increased (Figure 4B). Treatment with tacrolimus at both
100 and 1,000 nM dosages markedly enhanced SOCS3
mRNA expression (P <0.05 of both). However, both SOCS1
and CIS1 were not affected by tacrolimus treatment.
In the assessment of the effects of tacrolimus on the
expression of RANKL and SOCS3, tacrolimus markedly
increased the expression of the SOCS3 protein in a
dose-dependent manner, as evidenced by western blot
analysis (Figure 4C). Tacrolimus treatment (1 µM) in
IL-6/sIL-6R-induced FLS enhanced SOCS protein
expression, but significantly reduced expressions of
RANKL and two transcription factors, the activated
form of NF-B and NFATc1 (Figure 4D). In SOCS3
knockdown FLS, overexpression of RANKL, p-NF-B,
and NFATc1 was seen under stimulation of IL-6/sIL-6R.
In contrast, addition of tacrolimus in SOCS3-knockdown
FLS significantly attenuated overexpressions of these
molecules. This could suggest that enhanced SOCS3
expression by addition of tacrolimus contributed to the
down-regulation of NF-B and NFATc1 transcription
factors in SOCS3 knockdown cells. Immunofluorescence
studies also consistently demonstrated that tacrolimus
increased the expression of SOCS3 in IL-6/sIL-6R-
stimulated FLS (Figure 4E).
Figure 1 The effect of the IL-6/sIL-6R complex on RANKL, JAK2, STAT3 in fibroblast-like synoviocytes (FLS). (A) Stimulation of FLS with
IL-6 and sIL-6R at several different concentrations (0, 30, 50, 100 ng of both) for 30 minutes induced RANKL protein expression in a dose-
dependent manner. In contrast, expression of OPG protein was gradually inhibited under the same conditions. (B) Treatment with IL-6/sIL-6R
(100 ng of both) for 30 minutes in control synoviocytes increased the expression of SOCS3, p-JAK2, p-STAT3, and RANKL proteins. In SOCS3-
siRNA transfected FLS, expression of p-JAK2, p-STAT3, and RANKL under IL-6/sIL-6R stimulation (100 ng/ml each) for 30 minutes was significantly
increased compared to control synoviocytes. Data are determined in three independent experiments. IL-6, interleukin-6; JAK2, Janus activated
kinase; OPG, osteoprotegerin; RANKL, receptor activator of NF-B ligand; sIL-6R, soluble interleukin-6 receptor; SOCS3, suppressor of cytokine
signaling 3; STAT3, signal transducer and activator of transcription-3.
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The TRAP staining assay for osteoclasts using PBMC
obtained from RA patients was performed to confirm
the inhibitory effect of tacrolimus on osteoclast differen-
tiation. Tacrolimus suppressed osteoclast differentiation
in a dose-dependent manner, as illustrated in Figure 5A.
The number of TRAP positive cells was significantly
reduced after addition of 0.5 or 10 µM of tacrolimus
(P <0.05 and P <0.01, respectively) (Figure 5B).
Discussion
There is some evidence indicating that RANKL plays an
important role as a regulator of osteoclastogenesis in the
pathogenesis of RA [4]. It is well known that RANKL
arises from osteoblast/stromal cells and activated T lym-
phocytes [1,19]. Pro-inflammatory cytokines including
TNF-a, IL-17, and IL-1 are involved in the regulation of
RANKL mRNA levels and proteins produced by FLS in
mice and humans with RA [3-5]. Two previous studies
reported the induction of RANKL by TNF-a, IL-17, and
IL-1b in RA FLS [3,5]. Hashizume et al. demonstrated
that both TNF-a and IL-17 increased RANKL expression
only in association with sIL-6R [4]. Furthermore, they
showed that IL-6 also stimulated RANKL expression in
FLS in the presence of sIL-6R. In this study, co-treatment
Figure 2 The therapeutic effect of tacrolimus on inflammation and bone erosion in a serum-induced arthritis mouse model. (A) Before
immunization of C57BL/6 mice with K/BxN serum, tacrolimus (1 mg/kg) was intraperitoneally introduced four times for a week. At day 10, the
experimental mice were sacrificed. Serum-induced arthritic mice pretreated with tacrolimus showed less paw swelling compared to those not
treated with tacrolimus. Histological findings demonstrated protection against joint damage in the cartilage, bone, and synovium of tacrolimus-
treated mouse joints. (B) Ankle thickness in the tacrolimus-treated mice was significantly less than that of non-treated serum-induced arthritis
mice on days 8 and 10 (*P <0.05). (C) Semi-quantitative analysis for inflammation and bone erosion indicated fewer inflammatory changes and
less bone destruction in tacrolimus-treated mice compared to untreated mice (*P <0.05). (D) Tacrolimus treatment significantly reduced RANKL
mRNA expression in the affected joints of mice with serum-induced arthritis (*P <0.05). In contrast, the reduction in OPG mRNA expression in
serum-induced arthritis was reversed with treatment by tacrolimus (*P <0.05). SOCS3 mRNA expression also was increased in arthritic joints
treated with tacrolimus (*P <0.05 versus serum-induced arthritis not treated with tacrolimus). OPG, osteoprotegerin; RANKL, receptor activator of
NF-B ligand; SIA, serum-induced arthritis; SOCS3, suppressor of cytokine signaling 3; Tac, tacrolimus.
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of FLS with IL-6 and sIL-6R significantly increased
the protein and mRNA levels of RANKL. This suggests
that activation of the IL-6 trans-signaling pathway might
trigger osteoclastogenesis through enhanced RANKL
expression in FLS of subjects with RA.
IL-6 binding to sIL-6R activates JAK tyrosine kinase
and STAT transcriptional factor. Because its tyrosine
phosphorylation was detected exclusively in synovial
tissues of RA but not those of osteoarthritis, STAT3 is
considered a crucial molecule in the pathogenesis of RA
[10]. The IL-6/sIL-6R-treated stromal/osteoblastic cell
line (UAMS-32) with dominant negative-STAT3 protein
was blocked to induce RANKL expression [9]. These
findings suggest that the regulation of STAT3 is critical
for the control of osteoclastogenesis by activation of
gp-130-mediated cytokines. Treatment of IL-6/sIL-6R-
stimulated FLS with parthenolide, a STAT inhibitor,
reduced the expression of RANKL mRNA [4]. There-
fore, STAT3 activation is essential for transcription in
osteoclastogenesis through regulation of RANKL expres-
sion in the IL-6/sIL-6R-activated signaling pathway.
SOCS molecules, a family of eight different intracellular
Figure 3 Regulatory effect of tacrolimus on RANKL and OPG expression in FLS under IL-6/sIL-6R stimulation. (A) After pretreatment of
cultured FLS with IL-6/sIL-6R (100 ng of both), incubation with tacrolimus at several concentrations led to a consistently marked reduction of
RANKL at the mRNA (*P <0.001 at 10, 100, 1,000 nM of tacrolimus) and protein levels (‡P <0.05 at 100 nM and †P <0.01 1,000 nM of tacrolimus).
In contrast, tacrolimus at dosages of 100 and 1,000 nM significantly increased levels of OPG mRNA (*P <0.001 for each dosage). Expression of
OPG protein was consistently observed (†P <0.01 of 100 and 1,000 nM). (B) In western blot analysis for RANKL expression after tacrolimus
treatment, tacrolimus was found to inhibit RANKL expression in FLS stimulated by IL-6/sIL-6R (100 ng of both). In contrast, OPG expression was
increased following tacrolimus treatment. (C) Tacrolimus was shown to inhibit the expression of RANKL in FLS after stimulation with IL-6/sIL-6R
in the immunofluorescence assay. (D) The inhibitory effect of tacrolimus (1 µM) on RANKL expression was more prominent than that of other
anti-inflammatory drugs such as methotrexate (1 µg) and dexamethasone (1 µg). OPG mRNA expression was increased by tacrolimus and
methotrexate but not by dexamethasone. (*P <0.001, †P <0.01, ‡P <0.05 versus IL-6/sIL-6R-treated FLS). Data are determined in three
independent experiments. FLS, fibroblast-like synociocytes; IL-6, interleukin-6; OPG, osteoprotegerin; RANKL, receptor activator of NF-B ligand;
sIL-6R, soluble interleukin-6 receptor.
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proteins, were first identified as negative feedback fac-
tors for cytokine-related responses [20]. Now, SOCS
proteins are considered important players in the regula-
tion of the cytokine-JAK-STAT signaling pathway. Both
SOCS1 and SOCS3 have been identified as potential
inhibitors of JAK tyrosine kinase activity [6]. There is
some evidence that SOCS3 is a crucial negative regula-
tor of IL-6 signaling. Prolonged phosphorylation in
SOCS3 gene-deficient mouse macrophages due to sti-
mulation with IL-6 suggests that SOCS3 plays an impor-
tant role in controlling the responses to IL-6 [21]. In the
present study, we found that the IL-6/sIL-6R complex in
cultured RA synoviocytes led to phosphorylation of
JAK2 and STAT3 molecules. In addition, the expression
of the SOCS3 protein was markedly increased after sti-
mulation with IL-6/sIL-6R. Furthermore, the IL-6/sIL-6R
complex resulted in increased phosphorylation of both
JAK2 and STAT3, as well as increased RANKL protein
expression in SOCS3 siRNA-transfected RA FLS compared
to control FLS. Our data suggest that RANKL expression
in FLS treated with IL-6/sIL-6R might be primarily depen-
dent on the JAK2-STAT3-SOCS3 signaling pathway.
Figure 4 The effect of tacrolimus on JAK2, STAT3, and SOCS3 in IL-6/sIL-6R-stimulated FLS. (A) Stimulation with IL-6/sIL-6R (100 ng of
both) induced phosphorylation of JAK2 and STAT3. However, tacrolimus reversed these changes, thereby significantly reducing the expression of
p-JAK2 and p-STAT3. (B) Tacrolimus treatment of IL-6/sIL-6R-stimulated FLS potently suppressed IL-6 expression. Among negative regulators of
the JAK-STAT signaling pathway, prominent induction of SOCS3 mRNA expression was induced by tacrolimus (†P <0.05 at 100 and 1,000 nM) in
comparison to IL-6/sIL-6R-stimulated FLS. Expression of SOCS1 and CIS1 mRNA was not similarly induced. (C) Tacrolimus enhanced the level of
SOCS3 protein in IL-6/sIL-6R-treated FLS in a dose-dependent manner. (D) In SOCS3 knockdown FLS, IL-6/sIL-6R induced overexpression of
RANKL, p-NF-B and NFATc1. In contrast, addition of tacrolimus induced SOCS3 expression and attenuated RANKL expression. The protein levels
of p-NF-B and NFATc1 were significantly reduced, in comparison to those in SOCS3 knockdown FLS without tacrolimus. (E) The
immunofluorescence assay indicated the presence of an increased number of SOCS3-positive cells after treatment with tacrolimus compared to
controls. Data are determined in three independent experiments. CIS1, cytokine-inducible SH2; IL-6, interleukin-6; JAK2, Janus activated kinase;
RANKL, receptor activator of NF-B ligand; sIL-6R, soluble interleukin-6 receptor; SOCS1, suppressor of cytokine signaling 1; SOCS3, suppressor of
cytokine signaling 3; STAT3, signal transducer and activator of transcription 3.
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Tacrolimus is a potent immunosuppressive drug. It
primarily plays a role in the inhibition of T cell activation
by targeting a calcium-dependent calcineurin phospha-
tase of the NFAT transcription factor [11]. Tacrolimus
reduced the number of TRAP-positive human mononuc-
lear cells (MNCs) expressing RANKL and M-CSF as well
as the formation of lacunar resorption pits in a previous
study [15]. Tacrolimus has a potent inhibitory effect on
osteoclast differentiation. Inspection of rat upper maxilla
treated with tacrolimus (1 mg/kg/day) for 60 days
demonstrated an increase in alveolar bone volume sec-
ondary to a decrease in osteoclast number compared
to rats treated with a drug vehicle [22]. Another study
suggested that the anti-osteoclastic effect of tacrolimus
might be explained by its induction of apoptosis in
osteoclasts [23].
However, data about the effect of tacrolimus on
RANKL expression in RA synoviocytes has not been
identified. Our study showed that tacrolimus inhibits
bone erosion in a serum-induced arthritis mouse model,
compared to serum-induced arthritis mice not treated
with tacrolimus. The effect on bone erosion was seen in
addition to the anti-inflammatory effect of tacrolimus
on synovial inflammation in arthritis. The mRNA levels
of RANKL measured in the ankles of serum-induced
arthritis models treated with tacrolimus were signifi-
cantly lower than those not treated with tacrolimus.
This result was confirmed by an in vitro experiment
using RA FLS treated with IL-6/sIL-6R. These findings
suggest that the protective role of tacrolimus against
bone erosion is related to the reduction of RANKL pro-
duction in tacrolimus-treated mice.
Inhibition of either STAT or JAK is considered an
important therapeutic target to prevent bone destruction
in RA [8,9,24]. The Pan-JAK inhibitor, pyridine 6,
significantly suppressed osteoclast differentiation and
bone resorption by inhibiting RANKL-induced NFATc1
expression in mouse bone marrow macrophage cultures
[24]. In an experiment using STAT3 knockout mice,
induction of RANKL was inhibited by stimulation with
IL-6 and IL-6R [9]. Recently Mori et al. provide evi-
dence that suppression of STAT3 might be beneficial by
inhibiting osteoclatogenesis mediated by the IL-6/
STAT3-dependent inflammatory cascade [8]. We inves-
tigated whether tacrolimus has an inhibitory effect on
RANKL production by blocking or attenuating JAK2
and STAT3 activity in cultured RA synoviocytes treated
with IL-6/sIL-6R. We observed that tacrolimus has inhi-
bitory effects on the phosphorylation of both JAK2 and
STAT3 in FLS stimulated with IL-6/sIL-6R. Our results
suggest that tacrolimus may be involved in the activation
of JAK-STAT signaling in RA synoviocytes. Furthermore,
we demonstrated that down-regulation of JAK-STAT
activation secondarily induced the expression of SOCS3,
a negative regulator of STAT, whereas the expression of
SOCS1 and CIS1 was not similarly induced. Functional
SOCS1 deficiency is mainly involved in an unregulated
response of IFN-g, resulting in neonatal defects in
SOCS-/- mice [25]. The phenotypes of CIS transgenic
mice are remarkably similar to those found in STAT5
KO mice, suggesting that CIS is an important regulator
of STAT5-mediated cytokine responses [26]. However,
SOCS3 is considered a crucial determinant of IL-6 signal-
ing through negative feedback. This study also revealed
that tacrolimus, a known inhibitor of JAK2 and STAT3
phosphorylation, increased SOCS3 expression in IL-6/
sIL-6R-treated FLS.
The intracellular signaling pathways of RANKL-RANK
are mediated by activation of several crucial transcrip-
tion factors including NF-B and NFATc1 via TNF
Figure 5 The effect of tacrolimus on the formation of TRAP(+) multinucleated cells. (A) TRAP staining assay showed that 60 ng/ml of
RANKL and 50 ng/ml of M-CSF induced differentiation of PBMCs into TRAP (+) multinucleated cells, implicating osteoclasts (a). However,
addition of tacrolimus gradually decreased the number of TRAP (+) multinucleated osteoclasts in a tacrolimus dose-dependent manner (b to d)
(magnitude × 200). (B) Tacrolimus significantly suppressed number of TRAP(+) cells at 0.5 Mm and 1.0 Mm doses (*P <0.05 and †P <0.01). M-CSF,
macrophage colony-stimulating factor; RANKL, receptor activator of NF-B ligand; TRAP, tartrate-resistant acid phosphatase.
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receptor-associated factor-6 (TRAF-6) during osteoclas-
togenesis [27]. In this study, we suggest that overexpres-
sion of NF-B and NFATc1 in SOCS3 knockdown FLS
was suppressed by enhanced SOCS3 expression through
treatment with tacrolimus. Although tacrolimus could
directly inhibit activation of NFATc1, Banerjee et al.
showed that SOCS3 interacted with calcineurin and
then suppressed the activation of NFAT in primary
T cells [28]. Considering the effect of SOCS3 on activa-
tion of NF-B, SOCS3 inhibited IL-1-mediated NF-B
activation through suppression of ubiquitination of
TRAF-6 [29]. Based on this evidence, SOCS3 could play
a role as a crucial regulator of both NF-B and NFATc1
transcription factors.
Among several disease modifying anti-rheumatic drugs
for RA, MTX demonstrates marked potency as an inhi-
bitor of persistent synovial inflammation. Female Spra-
gue-Dawley rats treated with intraperitoneal MTX
injections exhibited a significant increase in urinary
hydroxyproline, a marker of bone resorption [30]. These
results suggest that bone metabolism in MTX-treated
subjects is related to the upregulation of osteoclast
activity. In contrast, in vitro, MTX therapy was shown
to decrease the RANKL:OPG ratio in cultured osteo-
blasts [31]. In the present study, we assessed the inhibi-
tory effect of RANKL expression and discovered that
MTX (100 nM) has an inhibitory effect on RANKL
production in IL-6-stimulated RA synoviocytes. The
influence of dexamethasone on RANKL expression has
been reported in different cell lines [32,33]. Our study
demonstrated that dexamethasone (1,000 nM) decreased
RANKL production in RA synoviocytes cultured with
IL-6/sIL-6R. Although the differential effect of dexa-
methasone on RANKL remained, its effect on RANKL
production in synoviocytes might be distinct from that
in other osteoblastic or osteoclastic cells.
Conclusions
In summary, the cytokine IL-6, together with sIL-6R,
has a pathogenic role in the development of RA through
its effects on synovial inflammation and bone destruc-
tion. As such, it is considered a promising therapeutic
target molecule. The intimate interaction between syno-
viocytes and osteoclasts contributes to the development
of bone erosion. RANKL has an essential role in the
regulation of osteoclast activation and differentiation.
Our study showed that FLS is another source of
RANKL production in synovial inflammation seen in
RA. In addition, we found that RANKL expression by
RA FLS depends on the JAK2-STAT3-SOCS3 signaling
pathway at both the mRNA and protein levels. As shown
in Figure 6, taken together these results indicate
that tacrolimus has an inhibitory effect on RANKL
expression in RA synoviocytes in both in vivo and in
Figure 6 Summary for the effect of calcineurin inhibitor, tacrolimus, on the regulation of RANKL expression through IL-6/sIL-6R/JAK2/
STAT3/SOCS3 pathway. IL-6, interleukin-6; JAK2, Janus activated kinase; RANKL, receptor activator of NF-B ligand; sIL-6R, soluble interleukin-6
receptor; SOCS3, suppressor of cytokine signaling 3; STAT3, signal transducer and activator of transcription 3.
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vitro experiments through its regulation of the JAK2-
STAT3-SOCS3 pathway.
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